account_balance
Investment manager · 13F filer · SEC CIK 1595855
Opaleye Management Inc.
Reported value$1.1Bas of Jun 30, 2026
Positions58 13 new, 9 sold out
Top 10 weight64.8%LQDA alone is 18%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
LQDALiquidia Corporation
17.7%Trimmed −4%
ETONEton Pharmaceuticals Inc
9.4%
HROWHarrow Inc
9.2%Trimmed −15%
IRONDisc Medicine Inc
5.7%Added +103%
URGNUrogen Pharma Ltd
4.8%
APGEApogee Therapeutics Inc
4.7%
MGTXMeiragtx Hldgs PLC
4.3%Added +67%
SLGLSol-gel Technologies Ltd
3.4%
RZLTRezolute Inc
3.0%
TGTX2.7%IMMXImmix Biopharma Inc
2.2%New
CBIOCrescent Biopharma Inc.
2.2%
LQDALiquidia Corporation
17.7%Trimmed −4%
ETON9.4%HROW9.2%IRON5.7%URGN4.8%APGE4.7%
MGTX4.3%SLGL3.4%RZLT3.0%TGTX2.7%IMMX2.2%CBIO2.2%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
LQDA Liquidia Corporation 17.7% Trimmed −4%ETON Eton Pharmaceuticals Inc 9.4% HeldHROW Harrow Inc 9.2% Trimmed −15%IRON Disc Medicine Inc 5.7% Added +103%URGN Urogen Pharma Ltd 4.8% Held
APGE Apogee Therapeutics Inc 4.7% Held
MGTX Meiragtx Hldgs PLC 4.3% Added +67%SLGL Sol-gel Technologies Ltd 3.4% HeldRZLT Rezolute Inc 3.0% HeldTGTX Tg Therapeutics Inc 2.7% HeldIMMX Immix Biopharma Inc 2.2% NewCBIO Crescent Biopharma Inc. 2.2% HeldWhat changed